drugset / Trial / NCT03944980
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte (PD1-T) combined with docetaxel in the second-line treatment of IIIB/IIIC/IV non-small cell lung cancer. Half of participants receive PD1-T combined with docetaxel, while the other half will receive docetaxel.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2021-06-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PD1-T cells | Cell therapy | 1e+10 cells | Intravenous |
| Background | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |